🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

In collaboration with Beth Israel Deaconess Medical Center, our new dedicated cancer hospital, projected to open in 2031, will strengthen Boston’s position as a global leader in oncology — and expand access to the most advanced care for patients across the region. Learn how

1/5 How reproducible are phase III oncology trials? 📊 With Alexander Sherry Erik van Zwet Ethan Ludmir MD et al. We analyzed 632 RCTs (~496,000 pts). The data offer both reassurance and caution for clinicians and researchers. pubmed.ncbi.nlm.nih.gov/40628175/ 👇#MsaouelLab

💫🌟🎯 Stereotactic Radiation for Primary Renal Cell Carcinoma: Is It Ready for Prime Time? OncoAlert European Association of Urology (EAU) ESMO - Eur. Oncology 📌 Erdem, Hannan, veronica mollica et al. 💥 “Ablation without incision — but are we ready to let go of histology?” 🟢 SBRT delivers: • 96% local control at 5 yrs

A warm invite to the Advanced Prostate Cancer Consensus Conference #APCCC26 in Lugano🇨🇭 👉REGISTER HERE: apccc.org/apccc-2026/ In an era of rapid innovation and expanding treatment options for advanced #ProstateCancer , APCCC provides a vital forum for clinicians and

Human kallikrein 2: A novel lineage-specific surface target in prostate cancer 🧬KLK2, a prostate-specific cell surface target, unlocked. 🔵3 therapies (bispecific T-cell, alpha-radioligand, CAR T) show strong preclinical activity. Clinical Cancer Research AACR OncoAlert Oncology Brothers

Metformin for patients with metastatic prostate cancer starting androgen deprivation therapy: a randomised phase 3 trial of the STAMPEDE platform protocol out on Lancet Oncology sciencedirect.com/science/articl… In the STAMPEDE phase 3 trial, researchers evaluated whether adding

Breaking News from ph3 Embark trial👉Enzalutamide+ADT improve overall survival (OS) vs. ADT alone in Non-Metastatic HSPC #Prostatecancer Congrats to Stephen Freedland, MD neal shore & team! Earlier enza works better! Link👉 rb.gy/iyc3f2 OncoAlert UroToday.com Prostate Cancer Foundation

Fantastic kick off of the II masterclass to discuss gaps in #Bladder cancer. First day pathology an non-Muscle invasive disease Multidisciplinary discussions full of interaction!!

🧬Single-cells omics provide highly informative and refined data about cancer biology. Yet, still need a roadmap to implement into the clinical practice! Must-read insights from Michael Skinnider et al. Cell Press OncoAlert Toni Choueiri, MD David Braun Eli Van Allen Yüksel Ürün

🇪🇸 Our Spanish multicenter study on SBRT for localized prostate cancer is featured by UroToday.com ! ✅ 251 pts, 12 centers ✅ Low acute toxicity ✅ Real-world data 🔗 urotoday.com/recent-abstrac… 🙏 Thanks @UroToday for highlighting our work! #SBRT #ProstateCancer #RadOnc

The OncoAlert🚨Weekly Round Up Covering the TOP of the week July 4-10, 2025 REGISTER at OncoAlert360.com OR oncoalert.m-pages.com/nhMpwe/oncoale… Discussing: ✅News From Industry: durvalumab in #BladderCancer ✅PRIM-B in metastatic #BreastCancer ✅Breastfeeding after breast

Underutilization of genomic testing in metastatic castration-resistant #ProstateCancer. Pedro C Barata, MD MSc FACP Case Comp Cancer Ctr joins Neeraj Agarwal, MD, FASCO Huntsman Cancer Institute discussing data revealing that nearly half of patients aren't receiving HRR testing despite its clinical importance and expressing

PSA responses with darolutamide + ADT in the #ARANOTE trial. Dr. Fred Saad CHUM joins Neeraj Agarwal, MD, FASCO Huntsman Cancer Institute to discuss how darolutamide + ADT triples undetectable PSA rates in mHSPC vs. ADT alone (62.6% vs. 18.5%). Patients achieving PSA <0.2 ng/mL see a 90% risk

🌏 APCCC is everywhere and now it’s in Seoul! Global minds unite for prostate cancer care. Genitourinary Masterclass! Advanced Prostate Cancer Consensus Conference #ProstateCancer #Oncology #GlobalOncology OncoAlert silke gillessen aurelius omlin

🏥 El #H12O, pionero en usar con éxito un radiofármaco en 18 pacientes con cáncer de piel no melanoma. ✈ Medicina Nuclear ha recibido a profesionales de Alemania y Australia, y de los hospitales Virgen de las Nieves y Gregorio Marañón para mostrarles esta terapia. #somosdel12

Starting the day with #ASCO25 Review at Ohio State Medical Oncology with an stellar lineup of speakers with our chairs Asrar AlAhmadi, MD, MAS-CR - أسرار الأحمدي & Ashish Manne a great opportunity for an update and networking with our colleagues from Ohio! Logan Roof, MD, MS Lingbin Meng Elshad Hasanov, MD, PhD The James

Thanks for advertising Advanced Prostate Cancer Consensus Conference and do not forget that registration is now open for 2026 on apccc.org for everyone interested. And we will for the first time also accept abstracts! Stay tuned for other news!

🌟Therapeutic Targeting of MMR-Deficient Cancers🌟 🖋️ Paul Johannet, Benoit Rousseau, Carol Aghajanian, Mike Foote Memorial Sloan Kettering Cancer Center Luis Diaz Nature Reviews Cancer nature OncoAlert “MMRd tumors: an immunogenic paradox — vulnerable yet resilient” 🔵 Immune-checkpoint inhibitors

Legacy isn’t just trophies, it’s people. mancity.fever PepTeam

🔬 La cirugía radioguiada con PSMA está transformando la detección de ganglios metastásicos en cáncer de próstata. En Latinoamérica, el camino ha iniciado. 🌎 💻Webinar - GRATUITO 🧵👇👇